Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model

Darpan I. Patel, Derek Wallace, Kira Abuchowski, Paul Rivas, Amber Gallegos, Nicolas Musi, Addanki P Kumar

Research output: Contribution to journalArticle

Abstract

Muscle loss is a debilitating side effect to prostate cancer (PCa) experienced by nearly 60% of men. The purpose of this study was to test the hypothesis that Nexrutine®, a bark extract from the Phellodendrum amurense, can protect against prostate cancer induced muscle loss in a similar manner as exercise, using the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Forty-five, 8- to 10-week old TRAMP mice were randomized to either control, Nexrutine® (600 mg/kg pelleted in chow) or exercise (voluntary wheel running). Mice were serially sacrificed at weeks 4, 8, 12, and 20, at which time either the left or right gastrocnemius muscle was harvested, weighted, and frozen. Proteolysis inducing factor (PIF), ubiquitin, and NF-κB concentrations were quantified using ELISA kits. Nexrutine® and exercise were equally able to protect TRAMP mice against PCa-induced muscle loss (P = 0.04). Both interventions decreased intramuscular PIF concentrations at 20 weeks compared to control (P < 0.05). A treatment effect was also observed when all time points were combined with exercise significantly lowering PIF concentrations (P < 0.01). Exercise significantly lowered intramuscular ubiquitin concentrations in weeks 4, 8, and 20 compared to control mice (P < 0.001). A treatment effect was also observed with exercise significantly lowering ubiquitin compared to control mice (P < 0.001). No significant changes were observed for NF-κB. The results of this investigation demonstrate that PCa-induced muscle loss can be attenuated with the herbal supplement Nexrutine®. This investigation provides preliminary evidence to support continued research into Nexrutine® as a potential exercise analog in protecting against muscle loss.

Original languageEnglish (US)
Article numbere14217
JournalPhysiological Reports
Volume7
Issue number16
DOIs
StatePublished - Jan 1 2019

Fingerprint

Prostatic Neoplasms
Muscle Neoplasms
Exercise
Muscles
Ubiquitin
Transgenic Mice
Proteolysis
Prostate
Adenocarcinoma
Running
Nexrutine
Skeletal Muscle
Enzyme-Linked Immunosorbent Assay
Therapeutics
Research

Keywords

  • atrophy
  • inflammation
  • natural product
  • neoplasm of the prostate
  • proteolysis-inducing factor

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model. / Patel, Darpan I.; Wallace, Derek; Abuchowski, Kira; Rivas, Paul; Gallegos, Amber; Musi, Nicolas; Kumar, Addanki P.

In: Physiological Reports, Vol. 7, No. 16, e14217, 01.01.2019.

Research output: Contribution to journalArticle

Patel, Darpan I. ; Wallace, Derek ; Abuchowski, Kira ; Rivas, Paul ; Gallegos, Amber ; Musi, Nicolas ; Kumar, Addanki P. / Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model. In: Physiological Reports. 2019 ; Vol. 7, No. 16.
@article{ae61af03942c424993be24f0775cb9f9,
title = "Nexrutine{\circledR} preserves muscle mass similar to exercise in prostate cancer mouse model",
abstract = "Muscle loss is a debilitating side effect to prostate cancer (PCa) experienced by nearly 60{\%} of men. The purpose of this study was to test the hypothesis that Nexrutine{\circledR}, a bark extract from the Phellodendrum amurense, can protect against prostate cancer induced muscle loss in a similar manner as exercise, using the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Forty-five, 8- to 10-week old TRAMP mice were randomized to either control, Nexrutine{\circledR} (600 mg/kg pelleted in chow) or exercise (voluntary wheel running). Mice were serially sacrificed at weeks 4, 8, 12, and 20, at which time either the left or right gastrocnemius muscle was harvested, weighted, and frozen. Proteolysis inducing factor (PIF), ubiquitin, and NF-κB concentrations were quantified using ELISA kits. Nexrutine{\circledR} and exercise were equally able to protect TRAMP mice against PCa-induced muscle loss (P = 0.04). Both interventions decreased intramuscular PIF concentrations at 20 weeks compared to control (P < 0.05). A treatment effect was also observed when all time points were combined with exercise significantly lowering PIF concentrations (P < 0.01). Exercise significantly lowered intramuscular ubiquitin concentrations in weeks 4, 8, and 20 compared to control mice (P < 0.001). A treatment effect was also observed with exercise significantly lowering ubiquitin compared to control mice (P < 0.001). No significant changes were observed for NF-κB. The results of this investigation demonstrate that PCa-induced muscle loss can be attenuated with the herbal supplement Nexrutine{\circledR}. This investigation provides preliminary evidence to support continued research into Nexrutine{\circledR} as a potential exercise analog in protecting against muscle loss.",
keywords = "atrophy, inflammation, natural product, neoplasm of the prostate, proteolysis-inducing factor",
author = "Patel, {Darpan I.} and Derek Wallace and Kira Abuchowski and Paul Rivas and Amber Gallegos and Nicolas Musi and Kumar, {Addanki P}",
year = "2019",
month = "1",
day = "1",
doi = "10.14814/phy2.14217",
language = "English (US)",
volume = "7",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

TY - JOUR

T1 - Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model

AU - Patel, Darpan I.

AU - Wallace, Derek

AU - Abuchowski, Kira

AU - Rivas, Paul

AU - Gallegos, Amber

AU - Musi, Nicolas

AU - Kumar, Addanki P

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Muscle loss is a debilitating side effect to prostate cancer (PCa) experienced by nearly 60% of men. The purpose of this study was to test the hypothesis that Nexrutine®, a bark extract from the Phellodendrum amurense, can protect against prostate cancer induced muscle loss in a similar manner as exercise, using the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Forty-five, 8- to 10-week old TRAMP mice were randomized to either control, Nexrutine® (600 mg/kg pelleted in chow) or exercise (voluntary wheel running). Mice were serially sacrificed at weeks 4, 8, 12, and 20, at which time either the left or right gastrocnemius muscle was harvested, weighted, and frozen. Proteolysis inducing factor (PIF), ubiquitin, and NF-κB concentrations were quantified using ELISA kits. Nexrutine® and exercise were equally able to protect TRAMP mice against PCa-induced muscle loss (P = 0.04). Both interventions decreased intramuscular PIF concentrations at 20 weeks compared to control (P < 0.05). A treatment effect was also observed when all time points were combined with exercise significantly lowering PIF concentrations (P < 0.01). Exercise significantly lowered intramuscular ubiquitin concentrations in weeks 4, 8, and 20 compared to control mice (P < 0.001). A treatment effect was also observed with exercise significantly lowering ubiquitin compared to control mice (P < 0.001). No significant changes were observed for NF-κB. The results of this investigation demonstrate that PCa-induced muscle loss can be attenuated with the herbal supplement Nexrutine®. This investigation provides preliminary evidence to support continued research into Nexrutine® as a potential exercise analog in protecting against muscle loss.

AB - Muscle loss is a debilitating side effect to prostate cancer (PCa) experienced by nearly 60% of men. The purpose of this study was to test the hypothesis that Nexrutine®, a bark extract from the Phellodendrum amurense, can protect against prostate cancer induced muscle loss in a similar manner as exercise, using the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Forty-five, 8- to 10-week old TRAMP mice were randomized to either control, Nexrutine® (600 mg/kg pelleted in chow) or exercise (voluntary wheel running). Mice were serially sacrificed at weeks 4, 8, 12, and 20, at which time either the left or right gastrocnemius muscle was harvested, weighted, and frozen. Proteolysis inducing factor (PIF), ubiquitin, and NF-κB concentrations were quantified using ELISA kits. Nexrutine® and exercise were equally able to protect TRAMP mice against PCa-induced muscle loss (P = 0.04). Both interventions decreased intramuscular PIF concentrations at 20 weeks compared to control (P < 0.05). A treatment effect was also observed when all time points were combined with exercise significantly lowering PIF concentrations (P < 0.01). Exercise significantly lowered intramuscular ubiquitin concentrations in weeks 4, 8, and 20 compared to control mice (P < 0.001). A treatment effect was also observed with exercise significantly lowering ubiquitin compared to control mice (P < 0.001). No significant changes were observed for NF-κB. The results of this investigation demonstrate that PCa-induced muscle loss can be attenuated with the herbal supplement Nexrutine®. This investigation provides preliminary evidence to support continued research into Nexrutine® as a potential exercise analog in protecting against muscle loss.

KW - atrophy

KW - inflammation

KW - natural product

KW - neoplasm of the prostate

KW - proteolysis-inducing factor

UR - http://www.scopus.com/inward/record.url?scp=85071496762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071496762&partnerID=8YFLogxK

U2 - 10.14814/phy2.14217

DO - 10.14814/phy2.14217

M3 - Article

C2 - 31456341

AN - SCOPUS:85071496762

VL - 7

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 16

M1 - e14217

ER -